The team is focused on understanding the complexities of the human and cancer genome and how genomic variation has shaped human evolution and health, cancer evolution, risk and outcomes. The team is using and developing an array of genomic tools from whole genome mapping, whole genome sequencing, exome sequencing, mitochondrial genome sequencing, high-throughput genotyping, Y-chromosome analysis and admixture mapping to capture genomic complexity, while computational and molecular-based methods are used to predict biological impact.

The most complex of the human genomes, specifically the earliest derived (most divergent or genetically distinct) and highly admixed human populations from Southern Africa, and the complex cancer genome of the prostate, form the focus of our laboratory. To address the complex genomics of early-derived human diversity and prostate cancer, the team is actively involved in adopting new state-of-the-art technologies.